Review of Tobramycin Dosing in Pediatric Patients With Cystic Fibrosis.

ABSTRACT:

Objective

An institution's tobramycin pharmacokinetics (PK) database was reviewed to evaluate the efficacy and safety of empiric tobramycin dosing and monitoring strategies used in pediatric patients with cystic fibrosis (CF). The relationship between patient age and tobramycin dosing needed to achieve the area under the curve (AUC) goal was investigated.

Methods

Retrospective chart review was performed for patients who received tobramycin during a CF exacerbation from 2009 to 2019 who received PK monitoring by pediatric pharmacists. Tobramycin dosing needed to achieve an AUC of 100 mg·hr/L was calculated for each patient. Serum creatinine and concomitant nephrotoxin use were collected as surrogate nephrotoxicity endpoints to evaluate safety.

Results

Goal AUC (100 ± 1

SUBMITTER: Imburgia TA 

PROVIDER: S-EPMC9901314 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature